Long-term combination therapy with Metformin and Oxymetholone in a Fanconi Anemia mouse model
Craig DorrelliD, A. Mack Peters, Qing‐Shuo ZhangiD, Niveditha Balaji, Kevin Baradar, Makiko Mochizuki‐KashioiD, Angela M. MajoriD, Milton J. FinegoldiD, Chih‐Wei LiuiD, Kun LüiD, Markus GrompeiD
Abstract
Fanconi Anemia (FA) is a disease caused by defective DNA repair which manifests as bone marrow failure, cancer predisposition, and developmental defects. Mice containing inactivating mutations in one or more genes in the FA pathway partially mimic the human disease. We previously reported that monotherapy with either metformin (MET) or oxymetholone (OXM) improved peripheral blood (PB) counts and the number and functionality of bone marrow (BM) hematopoietic stem progenitor cells (HSPCs) number in Fancd2-/- mice. To evaluate whether the combination treatment of these drugs has a synergistic effect to prevent bone marrow failure in FA, we treated cohorts of Fancd2-/- mice and wild-type controls with either MET alone, OXM alone, MET+OXM or placebo diet. Both male and female mice were treated from age 3 weeks to 18 months. The OXM treated animals showed modest improvements in blood parameters including platelet count (p=0.01) and hemoglobin levels (p<0.05). In addition, the percentage of quiescent HSC (LSK) was significantly increased (p=0.001) by long-term treatment with MET alone. However, the absolute number of progenitors, measured by LSK frequency or CFU-S, was not significantly altered by MET therapy. The combination of metformin and oxymetholone did not result in a significant synergistic effect on any parameter. Male animals on MET+OXM or MET alone were significantly leaner than controls at 18 months, regardless of genotype. Gene expression analysis of liver tissue from these animals showed that some of the expression changes caused by Fancd2 deletion were partially normalized by metformin treatment. Importantly, no adverse effects of the individual or combination therapies were observed, despite the long-term administration. Highlights- Long-term coadministration of metformin in combination oxymetholone is well tolerated by Fancd2-/- mice. - HSC quiescence in mutant mice was enhanced by treatment with metformin alone. - Metformin treatment caused a partial normalization of gene expression in the livers of mutant mice.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 2
- FWCI
- 0.53
- Field percentile
- top 40%
- Organism
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Recipient-driven metabolic and epigenetic remodeling of donor hematopoietic cells after transplantation in Fanconi Anemia.
Matilde Balbi, Stefano Regis, … Enrico Cappelli·bioRxiv·Oct 28, 2026
- FANCD2 Alleviates Physiologic Replication Stress in Fetal Liver HSC
Makiko Mochizuki‐Kashio, Young me Yoon, … Peter Kurre·bioRxiv·Sep 30, 2020
- In vivo assessment of differential toxicity of cancer treatment drugs in Fanconi Anemia
Craig Dorrell, Sebastian Restrepo Cruz, … Markus Grompe·bioRxiv·Nov 21, 2025
- In Utero Hematopoietic Stem Cell Transplant for Fanconi Anemia
Leah Swartzrock, Carla Dib, … Agnieszka D. Czechowicz·bioRxiv·May 9, 2024
- Development of a mouse model for spontaneous oral squamous cell carcinoma in Fanconi anemia
R. Errazquin, A. Page, … R. Garcia-Escudero·bioRxiv·Jun 5, 2022
- miR-29a-3p and TGF-beta Axis in Fanconi Anemia: Mechanisms Driving Metabolic Dysfunction and Genome Stability
Nadia Bertola, Stefano Regis, … Silvia Ravera·Cellular and Molecular Life SciencesPeer-reviewed·Jun 24, 2025